NOTCH2 and pancreatic adenocarcinoma: Notably, NOTCH2 also demonstrated excellent prognostic accuracy for 5-year survival, with an AUC>0.9 in the TCGA-PAAD cohort, which was validated in the GSE28735 cohort (Figure 5D).